Loading clinical trials...
Loading clinical trials...
Multi centre, prospective, non interventional study in 200-240 UK relapsing remitting multiple sclerosis patients. Patients will complete questionnaires at baseline, 3, 6 and 12 months.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT04047628 · Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, and more
NCT06663111 · Relapsing Remitting Multiple Sclerosis
NCT06282081 · Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
NCT04602390 · Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis
NCT06949956 · Relapsing Remitting Multiple Sclerosis
Novartis Investigative Site
Truro, Cornwall
Novartis Investigative Site
Swansea, England
Novartis Investigative Site
Romford, Essex
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions